CERO: CERo Therapeutics Holdings, Inc. - Summary | Jitta

CERo Therapeutics Holdings, Inc.

NASDAQ:CERO

Notice
Stock data is unavailable or the company’s delisted.
Price
$0.07
Loss Chance
59.6%
n/aJITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Sorry, the data is not yet available for this stock.
Jitta Factors
Growth Opportunity (0)
Recent Business Performance (17)
Financial Strength (31)
Return to Shareholders (21)
Competitive Advantage (9)
Jitta Signs
Cash Conversion CycleLess than 30 days
Recent Business PerformanceEarning decline 5588.51% in the last year
Key Stats
Jitta Score
Jitta Line
n/a
100.00%
2.21
139.52%
3.05
206.95%
Biotechnology
5.50
49.82%
6.36
42.71%
6.93
32.46%
COMPANY DESCRIPTION
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.